UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Volltextzugriff (PDF)

The role of tumor-associated macrophages in breast cancer progression

International journal of oncology, 2013-07, Vol.43 (1), p.5-12

2013

Volltextzugriff (PDF)

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1726-1731

2013

Volltextzugriff (PDF)

The molecular portraits of breast tumors are conserved across microarray platforms

BMC genomics, 2006-04, Vol.7 (1), p.96-96, Article 96

2006

Volltextzugriff (PDF)

Advances in Breast Cancer: Pathways to Personalized Medicine

Clinical cancer research, 2008-12, Vol.14 (24), p.7988-7999

2008

Volltextzugriff (PDF)

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

Modern pathology, 2006-02, Vol.19 (2), p.264-271

2006

Volltextzugriff (PDF)

Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Therapeutic Advances in Medical Oncology, 2016-09, Vol.8 (5), p.351-359

2016

Volltextzugriff (PDF)

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4515-4521

2009

Volltextzugriff (PDF)

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Nature communications, 2024-03, Vol.15 (1), p.2691-2691, Article 2691

2024

Volltextzugriff (PDF)

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Nature communications, 2024-05, Vol.15 (1), p.3957-3957, Article 3957

2024

Volltextzugriff (PDF)

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Clinical cancer research, 2015-06, Vol.21 (12), p.2771-2779

2015

Volltextzugriff (PDF)

Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer

The lancet oncology, 2024-03, Vol.25 (3), p.269-270

2024

Volltextzugriff (PDF)

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations

Breast cancer research : BCR, 2023-05, Vol.25 (1), p.58-58, Article 58

2023

Volltextzugriff (PDF)

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions

Reviews on recent clinical trials, 2007-05, Vol.2 (2), p.111-116

Nanda, Rita

2007

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002597

2021

Volltextzugriff (PDF)

Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities

Journal of clinical neuroscience, 2015-04, Vol.22 (4), p.632-637

2015

Volltextzugriff (PDF)

Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer

Integrative cancer therapies, 2023-01, Vol.22, p.15347354231185122-15347354231185122

2023

Volltextzugriff (PDF)

Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study

JMIR cancer, 2024-07, Vol.10, p.e55438

2024

Volltextzugriff (PDF)

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016

Journal of translational medicine, 2017-10, Vol.15 (1), p.205-21, Article 205

2017

Volltextzugriff (PDF)

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Breast cancer research : BCR, 2020-02, Vol.22 (1), p.22-22, Article 22

2020

Volltextzugriff (PDF)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Cancers, 2022-09, Vol.14 (18), p.4436

2022

Volltextzugriff (PDF)

Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence

NPJ breast cancer, 2023-04, Vol.9 (1), p.25-25, Article 25

2023

Volltextzugriff (PDF)

Novel therapies for triple-negative breast cancer

Clinical advances in hematology & oncology, 2020-12, Vol.18 (12), p.799

Nanda, Rita

2020

Volltextzugriff (PDF)

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies

PLoS medicine, 2006-12, Vol.3 (12), p.e486-e486

2006

Volltextzugriff (PDF)

1 – 25 von 339

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(305)
Mit Volltextzugriff
(272)

Publikationsform

Sprache

Englisch
(339)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(132)
Humans
(103)
Oncology
(94)
Female
(88)
Breast Cancer
(61)
Middle Aged
(54)
Adult
(49)
Aged
(37)
Breast Neoplasms - Drug Therapy
(36)
Chemotherapy
(36)
Tumors
(28)
Breast Neoplasms - Pathology
(27)
Patients
(27)
Breast Neoplasms - Genetics
(25)
Cancer Therapies
(25)
Immunotherapy
(23)
Medicine
(23)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Triple Negative Breast Neoplasms - Drug Therapy
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(23)

Menü

Weitere Dienste

Einstellungen

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

The role of tumor-associated macrophages in breast cancer progression

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

The molecular portraits of breast tumors are conserved across microarray platforms

Advances in Breast Cancer: Pathways to Personalized Medicine

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

Concepts and targets in triple-negative breast cancer: recent results and clinical implications

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities

Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer

Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence

Novel therapies for triple-negative breast cancer

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies

Suchergebnisse filtern